CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 24 enrolled
Drug / intervention
Enlighten Laser +1 moredevice
Likely dose
Not stated in record
Key inclusion· 6
  • ✓Age 30-90 years (inclusive)
  • ✓Fitzpatrick Skin Type I-III
  • ✓≥4 lentigines on hand(s)
  • ✓Desires non-invasive, non-ablative lentigine treatment
Key exclusion· 10
  • ✕Any prior cosmetic treatment to target area within 6 months (laser, light-based procedures, surgery)
  • ✕Systemic retinoid use (e.g., isotretinoin) within 6 months
  • ✕Topical medications on hands within 1 month: antibiotics, benzoyl peroxide, retinoids, corticosteroids, hydroquinone, or alpha-hydroxy >8%
  • ✕History of malignant tumors in target area

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02763072
NCT02763072N/ACompleted
CompareCT.gov

A Single-Center 2-Arm Study of the Enlighten and Excel V Laser for Lentigines on the Hands

Cutera Inc.·interventional·Posted May 5, 2016·Updated Jun 2, 2023

In Brief

A clinical study evaluating Enlighten Laser and Excel V Laser for Lentigines. Completed, enrolled 24 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the effectiveness and safety of two laser systems for improvement of lentigines on the hands.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLentigines
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 5, 2016
Enrollment StartApr 1, 2016
Primary CompletionJun 1, 2017
Study CompletionJun 26, 2017
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 10.2 years ago

Interventions

Enlighten Laserdevice

Excel V Laserdevice